Four-Pronged attack tested against Tough-to-Treat sarcoma
NCT ID NCT07205185
Summary
This study is testing a combination of four different treatments for people with advanced soft tissue sarcoma that has continued to grow after initial therapy. The treatment includes an immunotherapy drug (QL1706), a chemotherapy drug (eribulin), a targeted therapy (anlotinib), and radiation. The main goal is to see if this combination can shrink tumors and control the disease for people who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.